Animal studies are under way, human trial protocols are taking shape and drug makers are on alert. All the international health community needs now is a human vaccine for the bird flu pandemic sweeping a cluster of Asian countries.
The race for a vaccine began after the first human case emerged in Hong Kong in 1997. Backed by the World Health Organization (WHO), three research teams in the US and UK are trying to create a seed virus for a new vaccine. Their task is formidable, but researchers remain optimistic." There are obstacles, but most of the obstacles have been treated sensibly," says Richard Webby, a virologist at St. Jude Children’s Research Hospital in Memphis, Tennessee.
The biggest challenge is likely to be the rapidly mutating virus. Candidate vaccines produced last year against the H5N1 virus are ineffective against this year’s strain. Scientists will have to constantly monitor the changes and try to tailor the vaccine as the virus mutates. They can’t wait to see which one comes next.
The urgency stems from fears that I-ISN1 will combine with a human flu virus, creating a pathogen(病原体) that could be transmitted from person to person. But if people have no immunity to the virus, the strain may not mutate as rapidly in people as it does in birds.
To quickly generate the vaccine, researchers are using reverse genetics, which allows them to skip the long process of searching through reassorted viruses for the correct genetic combination. Instead, scientists clone sequences for hemagglutinin(红血球凝聚素) and neuraminidase(神经氨酸苷酶), the two key proteins in the virus. The sequences are then combined with human influenza genes to create a customized reference strain.
Because products developed with reverse genetics have never been tested in humans, the candidate vaccines will first have to clear regulatory review. In anticipation, the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) are both preparing pandemic response plans. The EMEA has produced a fist-track licensing program, an industry task force and detailed guidance for potential applicants.
In Europe, a reassortant influenza virus -- but not the inactivated vaccine -- produced by reverse genetics would be considered a genetically modified organism, and manufacturers would need approval from their national or local safety authorities. The WHO has prepared a preliminary biosafety risk assessment of pilot-lot vaccine, which could help speed up the review.
A preliminary version of their protocol calls for several hundred subjects, beginning with a group of young adults and gradually expanding to include those most susceptible to the flu -- children and the elderly." If we had product," says Lambert," it would probably be a couple of months at the earliest before we have early data in healthy adults./
During the developing of the vaccine, the biggest problem may probably be ______.

A:the combination of bird flu virus with human flu virus. B:the virus mutates in a short period. C:the vaccines are ineffective against the virus. D:the time is pressing for the scientists.

Animal studies are under way, human trial protocols are taking shape and drug makers are on alert. All the international health community needs now is a human vaccine for the bird flu pandemic sweeping a cluster of Asian countries.
The race for a vaccine began after the first human case emerged in Hong Kong in 1997. Backed by the World Health Organization (WHO), three research teams in the US and UK are trying to create a seed virus for a new vaccine. Their task is formidable, but researchers remain optimistic." There are obstacles, but most of the obstacles have been treated sensibly," says Richard Webby, a virologist at St. Jude Children’s Research Hospital in Memphis, Tennessee.
The biggest challenge is likely to be the rapidly mutating virus. Candidate vaccines produced last year against the H5N1 virus are ineffective against this year’s strain. Scientists will have to constantly monitor the changes and try to tailor the vaccine as the virus mutates. They can’t wait to see which one comes next.
The urgency stems from fears that I-ISN1 will combine with a human flu virus, creating a pathogen(病原体) that could be transmitted from person to person. But if people have no immunity to the virus, the strain may not mutate as rapidly in people as it does in birds.
To quickly generate the vaccine, researchers are using reverse genetics, which allows them to skip the long process of searching through reassorted viruses for the correct genetic combination. Instead, scientists clone sequences for hemagglutinin(红血球凝聚素) and neuraminidase(神经氨酸苷酶), the two key proteins in the virus. The sequences are then combined with human influenza genes to create a customized reference strain.
Because products developed with reverse genetics have never been tested in humans, the candidate vaccines will first have to clear regulatory review. In anticipation, the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) are both preparing pandemic response plans. The EMEA has produced a fist-track licensing program, an industry task force and detailed guidance for potential applicants.
In Europe, a reassortant influenza virus -- but not the inactivated vaccine -- produced by reverse genetics would be considered a genetically modified organism, and manufacturers would need approval from their national or local safety authorities. The WHO has prepared a preliminary biosafety risk assessment of pilot-lot vaccine, which could help speed up the review.
A preliminary version of their protocol calls for several hundred subjects, beginning with a group of young adults and gradually expanding to include those most susceptible to the flu -- children and the elderly." If we had product," says Lambert," it would probably be a couple of months at the earliest before we have early data in healthy adults./
The vaccine generated by reverse genetics is required to review in that ______.

A:it has strong side effect to the elderly. B:it may turn ineffective in a short period. C:it is useless in preventing the virus. D:it hasn’t been tested in humans.

The evolutionary process culminating in man was finally completed about 35,000 years ago with the appearance of Homo Sapiens, or "thinking man." (1) in broadest perspective, this represents the second major turning (2) in the course of (3) on this planet. The first occurred when life (4) out of inorganic matter. After that momentous (5) , all living forms evolved by adapting (6) their environment, as was evident during the climate turmoil of the Pleistocene. But with the (7) of man, the evolutionary process was (8) . No longer did genes adapt to environment. Instead, man adapted by changing the environment to (9) his genes. Today, a third (10) turning point appears (11) , as man’s growing knowledge of the structure and function of genes may soon enable him to (12) his genes as well as his environment.
Man, and only man, has been able to create a made-to-order environment, or culture, as it is called. The reason is (13) only man can symbolize, or (14) things and concepts divorced from here-and-now reality. Only he laughs, and only he knows that he will die. Only he has wondered (15) the universe and its origins, about his place in it and in the hereafter.
With these unique and revolutionizing abilities, man has been able to (16) with his environment without alteration. His culture in the new no biological way of having fur in the Arctic, water storage in the desert, and fins in the water. More concretely, culture (17) tools, clothing, ornaments, institutions, language, art forms, and religious beliefs and (18) . All these have served to adapt man to his physical environment and to his fellowman. Indeed, story of man is simply the story of a (19) of cultures that he has created, form his Paleolithic (20) to the present day.

10（）

A:invalid B:epochal C:periodical D:ineffective

The conception of poverty and what to (1) about it have changed over the decades. Under Social Darwinism the lazy and the (2) were supposed to be at the bottom of the economic ladder as (3) of the "law of survival of the fittest". Society was (4) as a network of self-sufficient families which provided for their own. (5) persons outside a household (orphans, the (6) elderly, and the crippled ) were provided outdoor relief grudgingly and as a temporary expedient (权宜之计). Although it was (7) that "the poor will always be with us", the individual was expected to improve himself (8) acts of his own will. Charity was thought to be the (9) of idleness. By keeping wages low, laborers would be (10) to work harder.
At about the turn of the century, the beginning of concern about natural (11) brought uneasiness about the possible spread of beggary. There was a potentially dangerous class in (12) of disease and disorder. The "poor" were (13) as different from "paupers" Paupers were individuals well (14) to being on the low end of the socioeconomic (15) Without shame or bitterness, they would not seek independence and a " (16) " life. For the mountaineers, the subsistence dwellers, and some slum dwellers, the lack of wealth, (17) has been argued, reflects a preference not to pay the psychological costs of the struggle for fiches or of adopting the middle class work ethic of striving. In (18) , the worthy poor struggled to (19) their lot against circumstances beyond their control: low wages, sickness, industrial (20) , widowhood (孀居) and so on.

2（）

A:inefficient B:invalid C:ineffective D:inaccessible

Text 2

During the developing of the vaccine, the biggest problem may probably be ______.

A:the combination of bird flu virus with human flu virus. B:the virus mutates in a short period. C:the vaccines are ineffective against the virus. D:the time is pressing for the scientists.

Text 2

The vaccine generated by reverse genetics is required to review in that ______.

A:it has strong side effect to the elderly. B:it may turn ineffective in a short period. C:it is useless in preventing the virus. D:it hasn’t been tested in humans.

Animal studies are under way, human trial protocols are taking shape and drug makers are on alert. All the international health community needs now is a human vaccine for the bird flu pandemic sweeping a cluster of Asian countries.
The race for a vaccine began after the first human case emerged in Hong Kong in 1997. Backed by the World Health Organization (WHO), three research teams in the US and UK are trying to create a seed virus for a new vaccine. Their task is formidable, but researchers remain optimistic." There are obstacles, but most of the obstacles have been treated sensibly," says Richard Webby, a virologist at St. Jude Children’s Research Hospital in Memphis, Tennessee.
The biggest challenge is likely to be the rapidly mutating virus. Candidate vaccines produced last year against the H5N1 virus are ineffective against this year’s strain. Scientists will have to constantly monitor the changes and try to tailor the vaccine as the virus mutates. They can’t wait to see which one comes next.
The urgency stems from fears that I-ISN1 will combine with a human flu virus, creating a pathogen(病原体) that could be transmitted from person to person. But if people have no immunity to the virus, the strain may not mutate as rapidly in people as it does in birds.
To quickly generate the vaccine, researchers are using reverse genetics, which allows them to skip the long process of searching through reassorted viruses for the correct genetic combination. Instead, scientists clone sequences for hemagglutinin(红血球凝聚素) and neuraminidase(神经氨酸苷酶), the two key proteins in the virus. The sequences are then combined with human influenza genes to create a customized reference strain.
Because products developed with reverse genetics have never been tested in humans, the candidate vaccines will first have to clear regulatory review. In anticipation, the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) are both preparing pandemic response plans. The EMEA has produced a fist-track licensing program, an industry task force and detailed guidance for potential applicants.
In Europe, a reassortant influenza virus -- but not the inactivated vaccine -- produced by reverse genetics would be considered a genetically modified organism, and manufacturers would need approval from their national or local safety authorities. The WHO has prepared a preliminary biosafety risk assessment of pilot-lot vaccine, which could help speed up the review.
A preliminary version of their protocol calls for several hundred subjects, beginning with a group of young adults and gradually expanding to include those most susceptible to the flu -- children and the elderly." If we had product," says Lambert," it would probably be a couple of months at the earliest before we have early data in healthy adults.

During the developing of the vaccine, the biggest problem may probably be （）

A:the combination of bird flu virus with human flu virus B:the virus mutates in a short period C:the vaccines are ineffective against the virus D:the time is pressing for the scientists

Animal studies are under way, human trial protocols are taking shape and drug makers are on alert. All the international health community needs now is a human vaccine for the bird flu pandemic sweeping a cluster of Asian countries.
The race for a vaccine began after the first human case emerged in Hong Kong in 1997. Backed by the World Health Organization (WHO), three research teams in the US and UK are trying to create a seed virus for a new vaccine. Their task is formidable, but researchers remain optimistic." There are obstacles, but most of the obstacles have been treated sensibly," says Richard Webby, a virologist at St. Jude Children’s Research Hospital in Memphis, Tennessee.
The biggest challenge is likely to be the rapidly mutating virus. Candidate vaccines produced last year against the H5N1 virus are ineffective against this year’s strain. Scientists will have to constantly monitor the changes and try to tailor the vaccine as the virus mutates. They can’t wait to see which one comes next.
The urgency stems from fears that I-ISN1 will combine with a human flu virus, creating a pathogen(病原体) that could be transmitted from person to person. But if people have no immunity to the virus, the strain may not mutate as rapidly in people as it does in birds.
To quickly generate the vaccine, researchers are using reverse genetics, which allows them to skip the long process of searching through reassorted viruses for the correct genetic combination. Instead, scientists clone sequences for hemagglutinin(红血球凝聚素) and neuraminidase(神经氨酸苷酶), the two key proteins in the virus. The sequences are then combined with human influenza genes to create a customized reference strain.
Because products developed with reverse genetics have never been tested in humans, the candidate vaccines will first have to clear regulatory review. In anticipation, the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) are both preparing pandemic response plans. The EMEA has produced a fist-track licensing program, an industry task force and detailed guidance for potential applicants.
In Europe, a reassortant influenza virus -- but not the inactivated vaccine -- produced by reverse genetics would be considered a genetically modified organism, and manufacturers would need approval from their national or local safety authorities. The WHO has prepared a preliminary biosafety risk assessment of pilot-lot vaccine, which could help speed up the review.
A preliminary version of their protocol calls for several hundred subjects, beginning with a group of young adults and gradually expanding to include those most susceptible to the flu -- children and the elderly." If we had product," says Lambert," it would probably be a couple of months at the earliest before we have early data in healthy adults.

The vaccine generated by reverse genetics is required to review in that （）

A:it has strong side effect to the elderly B:it may turn ineffective in a short period C:it is useless in preventing the virus D:it hasn’t been tested in humans

The World Health Organization estimates that about one-third of all people are infected with bacteria that cause tuberculosis. Most times, the infection remains inactive. But each year about eight million people develop active cases of TB, usually in their (1) . Two million people die (2) it. The disease has (3) with the spread of AIDS and drug-resistant forms of tuberculosis.
Current treatments take at least six months. Patients have to (4) a combination of several antibiotic drugs daily. But many people stop (5) they feel better. Doing that can (6) to an infection that resists treatment. Public health experts agree that a faster-acting cure for tuberculosis would be more effective. Now a study estimates just how (7) it might be. A professor of international health at Harvard University led the study. Joshua Salomon says a shorter treatment program would likely mean not just more patients (8) . It would also mean (9) infectious patients who can pass on their infection to others.
The researchers developed a mathematical model to examine the effects of a two-month treatment plan. They (10) the model with current TB conditions in Southeast Asia. The scientists found that a two-month treatment could prevent about twenty percent of new cases. And it might (11) about twenty-five percent of TB deaths. The model shows that these (12) would take place between two thousand twelve and two thousand thirty. That is. if a faster cure is developed and in wide use by two thousand twelve.
The World Health Organization (13) the DOTS program in nineteen ninety. DOTS is Directly Observed Treatment, Short-course. Health workers watch tuberculosis patients take their daily pills to make (14) they continue treatment.
Earlier this year, an international partnership of organizations announced a plan to expand the DOTS program. The ten-year plan also aims to finance research (15) new TB drugs. The four most common drugs used now are more than forty years old. The Global Alliance for TB Drug Development says its long-term goal is a treatment that could work in as few as ten doses.

7（）

A:effective B:ineffective C:expensive D:inexpensive

? ?阅读下面的短文，文中有15处空白，每处空白给出了4个选项，请根据短文的内容从4个选项中选择1个最佳答案。

A:effective B:ineffective C:expensive D:inexpensive